Researchers at University of California, San Diego School of Medicine have validated an EEG test to study and treat schizophrenia. The findings, published in two separate studies, offer a clinical test that could be used to help diagnose persons at risk for developing mental illness later in life, as well as an approach for measuring the efficacies of different treatment options.
One of the studies, reported online Oct. 23 in Schizophrenia Research, shows that schizophrenia patients don’t register subtle changes in reoccurring sounds as well as others and that this deficit can be measured by recording patterns of electrical brain activity obtained through electroencephalography (EEG).
The second, published online earlier this month in NeuroImage: Clinical, establishes a link between certain EEG tests and patients’ cognitive and psychosocial impairments, suggesting that the EEG test could be used to objectively measure the severity of a patient’s condition, and conversely that it might be possible to alleviate some of the symptoms of schizophrenia with specialized cognitive exercises designed to strengthen auditory processing.
“We are at the point where we can begin to bring simple EEG tests into the clinical setting to help patients,” said Gregory Light, PhD, associate professor of psychiatry and a co-author on both studies. “We think it may be possible to train some patients’ auditory circuits to function better. This could improve their quality of life, and possibly reduce common symptoms of schizophrenia such as hearing voices.”
In experiments, UC San Diego scientists and colleagues with the Consortium on the Genetics of Schizophrenia monitored volunteers’ electrical brain activity patterns as they listened to a sequence of beeps that occasionally included a discordant prolonged beep. The lengthier beeps were one-twentieth of a second longer than the standard beeps and occurred roughly 10 percent of the time.
A total of 1,790 people were tested at five sites nationwide as part of a National Institutes of Health-funded study to unravel the genetic basis of schizophrenia. Nine-hundred and sixty-six were schizophrenia patients; 824 were healthy control subjects.
The EEG data were analyzed for two auditory processing metrics. One is known as mismatch negativity (MMN). Measured in microvolts, MMN represents the difference between the brain’s response to the expected stream of beeps and its response to the singular, different ping. The other, called P3a, is a measure of the electrical energy emitted by the brain as it automatically shifts attention to the longer beep.
People with schizophrenia were consistently shown to have reduced MMN and P3a relative to those without the disease, suggesting they had a muted ability to detect and direct their attention to the discordant beep.
In the second study, researchers showed that measures of MMN and P3a were associated with the severity of a patient’s symptoms and their day-to-day real-world functioning.
Specifically, in a comparison of MMN and P3a measurements from 42 patients with schizophrenia and 47 non-psychiatric comparison subjects, scientists showed that differences in these auditory processing metrics accounted for approximately half of the variance in the severity of patients’ symptoms and their ability to perform tasks necessary for real‐world functioning.
The two studies further validate the ability to measure MMN and P3a with only one EEG electrode placed on the front of the scalp, meaning that the EEG testing can be conducted outside of academic research laboratories.
Researchers plan to use their studies’ findings to try to improve the quality of life for patients at the Alpine Special Treatment Center, a mental health rehabilitation and long-term care facility in eastern San Diego County.
“Our goal is to see if we can help people improve their brain functioning by providing daily cognitive exercises that are designed to sharpen their sensory information processing,” said Light, who is also associate director of the VISN-22 Mental Illness, Research, Education and Clinical Center (MIRECC) at the Veterans Affairs San Diego Healthcare System. “We will then use EEGs to see if we can identify markers that predict which patients are most likely to benefit from this form of treatment.”
Funding for the study in Schizophrenia Research was provided, in part, by the National Institute of Mental Health (grant R01 MH065571) and Brain and Behavior Research Foundation.
Co-authors include: Neal R. Swerdlow, Michael L. Thomas, Tiffany A. Greenwood, Marlena Pela, Richard F. Sharp, Joyce Sprock, David L. Braff, UC San Diego; Monica E. Calkins, Raquel E. Gur, Ruben C. Gur and Bruce I. Turetsky, University of Pennsylvania; Keith H. Nuechterlein and Catherine A. Sugar, UCLA; Laura C. Lazzeroni, Stanford University; Michael F. Green, UCLA and VA Greater Los Angeles Healthcare System, Los Angeles; Allen D. Radant and Debby W. Tsuang, University of Washington and VA Puget Sound Health Care System, Seattle; Larry J. Seidman and William S. Stone, Harvard Medical School and Beth Israel Deaconess Medical Center, Boston; Larry J. Siever and Jeremy M. Silverman, The Mount Sinai School of Medicine and James J. Peters VA Medical Center, New York; Ming T. Tsuang, UC San Diego and Harvard Institute of Psychiatric Epidemiology and Genetics.
Funding for the study in NeuroImage: Clinical was provided, in part, by National Alliance for Research on Schizophrenia, Brain and Behavior Research Foundation, Department of Veteran Affairs, Veterans Medical Research Foundation and National Institute of Mental Health (grants MH079777, MH042228, MH065571, MH094151, MH093453, MH094320, UL1TR000100 and MH081944).
Co-authors on the study include: Anthony J. Rissling and Scott Makeig, UC San Diego; Makoto Miyakoshi, UC San Diego and Japan Society for the Promotion of Science; Catherine A. Sugar, UCLA and Greater Los Angeles VA Healthcare System; and David L. Braff, San Diego VA Medical Center and UC San Diego.
# # #
Media contacts: Scott LaFee or Christina Johnson, 619-543-6163, email@example.com